Adnexus Therapeutics

Adnexus Therapeutics Appoints L. Patrick Gage, Ph.D., as Chairman of the Board of Directors

Adnexus Therapeutics Appoints L. Patrick Gage, Ph.D., as Chairman of the Board of Directors

September 25, 2006

Widely recognized industry leader to guide company advancing breakthrough class of protein therapeutics

Pervasis Therapeutics, Inc.

Pervasis Therapeutics' Vascugel(TM) Initiates U.S. Clinical Trials Following Successful FDA IND Review

Pervasis Therapeutics' Vascugel(TM) Initiates U.S. Clinical Trials Following Successful FDA IND Review

September 27, 2006

Pioneer in regenerative cell-based therapies and devices begins Phase I trials of first biologically-active treatment to ameliorate acute vascular injury

CGI Pharmaceuticals, Inc.

Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications

Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications

October 3, 2006

SOUTH SAN FRANCISCO, Calif. and BRANFORD, Conn., Oct. 3 -- Genentech, Inc. (NYSE: DNA - News) and CGI Pharmaceuticals, Inc. announced today that they have entered into an exclusive global collaboration agreement to discover, develop, manufacture and commercialize therapeutics for an undisclosed target for the potential treatment of multiple oncology and autoimmune indications.

TransMedics, Inc.

TransMedics Receives European Union CE Marking Designation for its Organ Care System

TransMedics Receives European Union CE Marking Designation for its Organ Care System

October 3, 2006

ANDOVER, Massachusetts, October 3 -- TransMedics, Inc., announced today that it has received CE Marking approval for its Organ Care System, the first and only system that allows human donor organs to be maintained in their normal functioning state outside the human body. This designation assures physicians and patients that the Organ Care System is compliant with EU health and safety requirements, allowing TransMedics to market and distribute the system within the European Union, as well as many other countries throughout Asia and the Middle East.

Helicos BioSciences Corporation

Helicos BioSciences Awarded ‘Revolutionary Genome Sequencing Technologies – The $1000 Genome’ Grant

Helicos BioSciences Awarded ‘Revolutionary Genome Sequencing Technologies – The $1000 Genome’ Grant

October 4, 2006

Recognition by National Human Genome Institute to Accelerate Research of Helicos Single Molecule Sequencing Technology

Helicos BioSciences Corporation

Helicos BioSciences Names Louise Mawhinney Vice President & Chief Financial Officer

Helicos BioSciences Names Louise Mawhinney Vice President & Chief Financial Officer

October 12, 2006

CAMBRIDGE, Mass.— October 12, 2006 --Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, announced today that it has named longtime financial executive Louise Mawhinney as Vice President and Chief Financial Officer.

Stanley N. Lapidus, President and CEO of Helicos, said, “We are pleased to have Louise join our executive team. Her operational expertise and deep experience with the financial markets is a great addition to my staff and provides a crucial skill set required for our continued evolution as a company.”

Morphotek, Inc.

Morphotek Raises $40 Million to Advance its Antibody Pipeline

Morphotek Raises $40 Million to Advance its Antibody Pipeline

October 12, 2006

Exton, PA, October 12, 2006 -- Morphotek® Inc., a privately held biopharmaceutical company focused on the discovery and development of therapeutic monoclonal antibodies, announced today the closing of a $40 million Series D financing. The financing was led by Investor Growth Capital of New York and included participation of new investors MDS Capital and Hunt BioVentures as well as existing investors Forward Ventures, Morgenthaler Ventures, SR One, Flagship Ventures, Burrill & Co., CB Health Ventures, and Rock Maple Ventures.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors

AVEO Pharmaceuticals Initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors

October 23, 2006

CAMBRIDGE, MA October 23, 2006 – AVEO Pharmaceuticals, Inc. (AVEO), a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that it has begun enrolling patients in a Phase I clinical study for AV-412, a next generation oral tyrosine kinase inhibitor of EGFR/HER2. The open-label, sequential dose escalation study will be conducted at several leading cancer institutions to examine the safety, tolerability and optimal dosing of AV-412.

Adnexus Therapeutics

Adnexus Therapeutics Announces Issuance of U.S. Patent for Broad Protection of New Therapeutic Class, Adnectins(TM)

Adnexus Therapeutics Announces Issuance of U.S. Patent for Broad Protection of New Therapeutic Class, Adnectins(TM)

October 23, 2006

Waltham, MA, October 23, 2006 – Adnexus TherapeuticsTM, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 7,115,396 with broad composition of matter claims to AdnectinTM proteins. Exclusively owned by Adnexus, this patent further expands the company’s ownership of Adnectins, a class of targeted biologics with broad applicability across many aspects of the biotechnology industry, including both therapeutics and diagnostics.

Harry Wilcox Joins Flagship Ventures as CFO and Partner

Harry Wilcox Joins Flagship Ventures as CFO and Partner

October 23, 2006

Harry Wilcox has joined Flagship Ventures as CFO and Partner. Harry will take over from Cheryl Goyette who will be leaving us during November to join a newly formed venture firm as their CFO. We are thankful for the many contributions made by Cheryl in managing our partnership finance activities over the last 8 years and look forward to continuing to excel in this area under the able leadership of Harry.